This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Feb;3(2):e56-7.

doi: 10.1016/S2352-3026(15)00288-4. Epub 2016 Jan 16.

New hope for patients with livedoid vasculopathy

Robert S Kirsner¹

Affiliations

Affiliation

¹ Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Electronic address: rkirsner@miami.edu.

PMID: 26853641
DOI: 10.1016/S2352-3026(15)00288-4

Comment

New hope for patients with livedoid vasculopathy

Robert S Kirsner. Lancet Haematol. 2016 Feb.

. 2016 Feb;3(2):e56-7.

doi: 10.1016/S2352-3026(15)00288-4. Epub 2016 Jan 16.

Author

Robert S Kirsner¹

Affiliation

¹ Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Electronic address: rkirsner@miami.edu.

PMID: 26853641
DOI: 10.1016/S2352-3026(15)00288-4

No abstract available

PubMed Disclaimer

Comment on

Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, Eveslage M, Drabik A, Goerge T. Weishaupt C, et al. Lancet Haematol. 2016 Feb;3(2):e72-9. doi: 10.1016/S2352-3026(15)00251-3. Epub 2016 Jan 16. Lancet Haematol. 2016. PMID: 26853646 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information